Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Buys $51,240.00 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III acquired 2,562 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were acquired at an average cost of $20.00 per share, for a total transaction of $51,240.00. Following the transaction, the insider owned 1,007,090 shares of the company’s stock, valued at approximately $20,141,800. This represents a 0.26% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Tuesday, January 20th, Group Gp Lp Column III bought 18,052 shares of Surrozen stock. The stock was acquired at an average cost of $19.60 per share, with a total value of $353,819.20.
• On Thursday, January 15th, Group Gp Lp Column III purchased 11,893 shares of Surrozen stock. The shares were acquired at an average price of $19.89 per share, for a total transaction of $236,551.77.
• On Wednesday, January 14th, Group Gp Lp Column III purchased 5,523 shares of Surrozen stock. The shares were acquired at an average price of $19.99 per share, for a total transaction of $110,404.77.
• On Tuesday, January 13th, Group Gp Lp Column III acquired 12,470 shares of Surrozen stock. The stock was acquired at an average cost of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Group Gp Lp Column III acquired 15,100 shares of Surrozen stock. The stock was acquired at an average price of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III bought 30,884 shares of Surrozen stock. The shares were bought at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III purchased 5,266 shares of Surrozen stock. The stock was bought at an average cost of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III purchased 315,457 shares of Surrozen stock. The shares were bought at an average price of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Stock Performance

Shares of NASDAQ SRZN opened at $20.00 on Friday. The business’s 50-day simple moving average is $19.26 and its 200-day simple moving average is $14.21. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $24.94. The firm has a market cap of $171.40 million, a price-to-earnings ratio of -0.90 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last announced its earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The company had revenue of $0.98 million for the quarter. As a group, equities research analysts forecast that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SRZN. Citadel Advisors LLC raised its position in shares of Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after buying an additional 3,424 shares during the last quarter. Geode Capital Management LLC increased its stake in Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after acquiring an additional 5,702 shares during the period. Acuta Capital Partners LLC raised its holdings in Surrozen by 5.0% in the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after acquiring an additional 8,415 shares in the last quarter. Stonepine Capital Management LLC lifted its position in shares of Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after acquiring an additional 20,247 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Surrozen by 21.7% in the 3rd quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after acquiring an additional 47,468 shares during the period. Institutional investors own 66.57% of the company’s stock.

Wall Street Analysts Forecast Growth

SRZN has been the topic of several recent analyst reports. Lifesci Capital upgraded shares of Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Wall Street Zen raised Surrozen to a “sell” rating in a research report on Friday, November 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.